About Decipher Labs Limited
Data last updated:
Decipher Labs Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 17 September 1986 and has been in existence for over 40 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24230TG1986PLC006781. It is a listed company as per MCA records. Its shares are listed on BSE: 524752.
The company has an authorised share capital of ₹10.5 Cr and a paid-up capital of ₹10.1 Cr. It was formerly known as R. A. Labs (India) Limited and Ra Labs Limited. It is led by directors including Dalavath Amar Singh (Whole-Time Director) and Gayathri Raghuram.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at A – 2 Q2 5th Floor Cyber Towers Hitech City, Hyderabad, Telangana, India – 500081.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹14.05 Cr, a decline of 37.9% compared to the previous year. For the same year it recorded a net loss of ₹3.09 Cr (net margin -22%) and EBITDA of -₹3.39 Cr (EBITDA margin -24.1%). The net worth stands at ₹20.67 Cr (down 9.6% YoY). Total assets are valued at ₹21.17 Cr (down 8.4% YoY).
Its group structure includes 1 subsidiary.
The company is associated with 2 brands: Combat Drugs and Decipher Labs. As per MCA filings, the company has open charges of ₹42.25 Lakh and satisfied charges of ₹1.4 Cr on record. Court records list 13 cases involving the company, including 5 filed by the company and 8 filed against it; 3 cases are pending. The company has 38 deals on record (38 market trades); the latest was in June 2024. Its 5 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 2 smaller; the largest is Dagon Pharmaceuticals Private Limited with revenue of ₹24.08 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website decipherlabs.in.
Company details
Name history
Decipher Labs has undergone 11 name changes throughout its history. The current legal name is Decipher Labs Limited.
| Company Name | Status |
|---|---|
| Decipher Labs Limited | Current |
| R. A. Labs (India) Limited | Previous |
| Ra Labs Limited | Previous |
| R.A Labs (India) Limited | Previous |
| R.A. Labs Limited | Previous |
| Combat Drugs Limited | Previous |
| Ra Labs (India) Limited | Previous |
| Combat Drugs And Softech Limited | Previous |
| R.A Labs Limited | Previous |
| 3I Labs Limited | Previous |
| 3Rd I. Labs Limited | Previous |
| R.A. Labs (India) Limited | Previous |
CIN history
Decipher Labs has one previous CIN (Corporate Identification Number): L24230AP1986PLC006781. The current CIN is L24230TG1986PLC006781, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230TG1986PLC006781 | Current |
| L24230AP1986PLC006781 | Previous |
Contact details
Decipher Labs Limited's registered office is in Hyderabad, Telangana. Its website is decipherlabs.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressA – 2 Q2 5th Floor Cyber Towers Hitech City, Hyderabad, Telangana, India – 500081
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Decipher Labs Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Decipher Labs operates two associated brands: Combat Drugs and Decipher Labs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Formulations are manufactured and custom services are provided in pharmaceuticals. | combatdrugs.in | |
| Healthcare company that develops and commercializes genomic tests for personalized cancer treatment, focusing on prostate and bladder cancer diagnosis and treatment planning | decipherlabs.in |
Business activity
The main business activity of Decipher Labs is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Decipher Labs Limited, buy the company report.
Financials of Decipher Labs Limited
FY 2025-26 filings availableDecipher Labs Limited reported revenue of ₹14.05 Cr (down 37.9% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 14.05 | 22.61 | 35.88 | 45.57 | 65.32 | 55.56 | 23.99 |
| Revenue growth | -37.9% | -37.0% | -21.3% | -30.2% | +17.6% | +131.6% | - |
| EBITDA | (3.39) | (7.23) | (0.94) | (10.62) | 6.02 | 3.49 | 2.53 |
| EBITDA margin | -24.1% | -32.0% | -2.6% | -23.3% | +9.2% | +6.3% | +10.6% |
| Profit before tax | (3.69) | (6.39) | (1.21) | (4.16) | 12.34 | 2.15 | 1.47 |
| Net profit | (3.09) | 0.26 | (1.51) | 3.77 | 11.37 | 1.41 | 1.10 |
| Net profit margin | -22.0% | +1.2% | -4.2% | +8.3% | +17.4% | +2.5% | +4.6% |
| EPS (₹) | (3.05) | (5.03) | (1.66) | (2.66) | 11.27 | 1.39 | 1.09 |
| Balance sheet | |||||||
| Total assets | 21.17 | 23.10 | 21.86 | 24.16 | 34.49 | 30.08 | 23.84 |
| Net worth | 20.67 | 22.86 | 21.86 | 23.21 | 24.17 | 13.69 | 12.56 |
| Total debt | 0.50 | 0.24 | 0.00 | 0.95 | 10.32 | 16.39 | 11.28 |
| Cash & bank | 0.74 | 2.81 | 9.31 | 7.42 | 15.41 | 6.98 | 1.47 |
| Net working capital | 15.95 | 18.39 | 12.90 | 16.07 | 30.76 | 13.90 | 11.13 |
| Cash flow | |||||||
| Cash from operations | (2.45) | (9.82) | 4.85 | (1.56) | 8.26 | 1.83 | (15.18) |
| Cash from investing | (0.24) | 3.07 | (1.79) | (4.28) | (1.13) | (0.31) | (0.01) |
| Cash from financing | 0.00 | 0.24 | (1.17) | (2.15) | 1.30 | 3.99 | 16.36 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.41 | 3.60 | 3.21 | 4.31 | 2.92 | 3.50 | 5.80 | 5.87 |
| Revenue growth (YoY) | -17.5% | +2.9% | -44.7% | -26.6% | -60.8% | - | - | - |
| Other income | 0.10 | 0.17 | 0.02 | 0.02 | 0.01 | 0.87 | 0.17 | 0.12 |
| EBITDA | (2.16) | 0.22 | (0.43) | 0.12 | (3.32) | (6.58) | (0.64) | (1.33) |
| EBITDA margin | -89.6% | +6.1% | -13.4% | +2.8% | -113.7% | -188.0% | -11.0% | -22.7% |
| Depreciation | 0.13 | 0.15 | 0.13 | 0.13 | 0.12 | 0.13 | 0.12 | 0.12 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (2.19) | 0.24 | (0.54) | 0.01 | (3.43) | (5.84) | (0.59) | (1.33) |
| Tax | 0.00 | 0.61 | 0.01 | 0.00 | 0.00 | (1.73) | 0.01 | 0.00 |
| Net profit | (2.19) | (0.37) | (0.55) | 0.01 | (3.43) | (4.11) | (0.60) | (1.33) |
| EPS (₹) | (2.16) | (0.35) | (0.53) | 0.02 | (3.39) | (4.07) | (0.59) | (1.31) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1.14 | 0.85 | 3.53 | 0.81 | 0.99 | 0.98 | 1.42 |
| Revenue growth | +34.1% | -75.9% | +335.8% | -18.2% | +1.0% | -31.0% | - |
| EBITDA | (0.22) | (0.45) | 0.02 | (2.60) | 0.36 | 0.03 | 0.16 |
| EBITDA margin | -19.3% | -52.9% | +0.6% | -321.0% | +36.4% | +3.1% | +11.3% |
| Profit before tax | (0.24) | (0.45) | 0.03 | (2.63) | 0.36 | 0.11 | 0.17 |
| Net profit | (0.25) | (0.45) | 0.03 | (0.30) | 0.36 | 0.11 | 0.17 |
| Net profit margin | -21.9% | -52.9% | +0.9% | -37.0% | +36.4% | +11.2% | +12.0% |
| EPS (₹) | (0.24) | (0.44) | 0.02 | (2.59) | 0.36 | 0.10 | 0.17 |
| Balance sheet | |||||||
| Total assets | 8.74 | 8.73 | 8.93 | 8.90 | 11.52 | 11.30 | 11.30 |
| Net worth | 8.24 | 8.49 | 8.93 | 8.90 | 11.52 | 11.16 | 11.07 |
| Total debt | 0.50 | 0.24 | 0.00 | 0.00 | 0.00 | 0.14 | 0.23 |
| Cash & bank | 0.03 | 0.05 | 0.03 | 0.06 | 0.05 | 0.02 | 0.03 |
| Net working capital | (0.09) | (0.13) | 0.15 | 0.10 | 2.52 | 2.62 | 2.77 |
| Cash flow | |||||||
| Cash from operations | (0.29) | (0.17) | (0.03) | (0.08) | 0.55 | 0.27 | (0.01) |
| Cash from investing | 0.00 | (0.05) | 0.00 | 0.09 | (0.38) | (0.19) | (0.07) |
| Cash from financing | 0.26 | 0.24 | 0.00 | 0.00 | (0.14) | (0.09) | 0.09 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.10 | 0.07 | 0.13 | 0.09 | 0.85 | 0.23 | 0.16 | 0.08 |
| Revenue growth (YoY) | -88.2% | -69.6% | -18.8% | +12.5% | +123.7% | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Total expenses | 0.17 | 0.24 | 0.14 | 0.20 | 0.78 | 0.39 | 0.25 | 0.15 |
| EBITDA | (0.07) | (0.17) | (0.01) | (0.11) | 0.07 | (0.16) | (0.09) | (0.07) |
| EBITDA margin | -70.0% | -242.9% | -7.7% | -122.2% | +8.2% | -69.6% | -56.3% | -87.5% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.07) | (0.17) | (0.01) | (0.11) | 0.07 | (0.16) | (0.09) | (0.05) |
| Tax | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.41 | 3.60 | 3.21 | 4.31 | 2.92 | 3.50 | 5.80 | 5.87 |
| Revenue growth (YoY) | -17.5% | +2.9% | -44.7% | -26.6% | -60.8% | - | - | - |
| Other income | 0.10 | 0.17 | 0.02 | 0.02 | 0.01 | 0.87 | 0.17 | 0.12 |
| EBITDA | (2.16) | 0.22 | (0.43) | 0.12 | (3.32) | (6.58) | (0.64) | (1.33) |
| EBITDA margin | -89.6% | +6.1% | -13.4% | +2.8% | -113.7% | -188.0% | -11.0% | -22.7% |
| Depreciation | 0.13 | 0.15 | 0.13 | 0.13 | 0.12 | 0.13 | 0.12 | 0.12 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (2.19) | 0.24 | (0.54) | 0.01 | (3.43) | (5.84) | (0.59) | (1.33) |
| Tax | 0.00 | 0.61 | 0.01 | 0.00 | 0.00 | (1.73) | 0.01 | 0.00 |
| Net profit | (2.19) | (0.37) | (0.55) | 0.01 | (3.43) | (4.11) | (0.60) | (1.33) |
| EPS (₹) | (2.16) | (0.35) | (0.53) | 0.02 | (3.39) | (4.07) | (0.59) | (1.31) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 14.05 | 22.61 | 35.88 | 45.57 | 65.32 | 55.56 | 23.99 |
| Revenue growth | -37.9% | -37.0% | -21.3% | -30.2% | +17.6% | +131.6% | - |
| Other income | 0.22 | 1.32 | 0.42 | 7.37 | 7.67 | 0.65 | 0.27 |
| Total expenses | 17.44 | 29.84 | 36.82 | 56.19 | 59.30 | 52.07 | 21.46 |
| Employee cost | 0.00 | 21.32 | 27.75 | 41.16 | 47.46 | 47.34 | 19.32 |
| EBITDA | (3.39) | (7.23) | (0.94) | (10.62) | 6.02 | 3.49 | 2.53 |
| EBITDA margin | -24.1% | -32.0% | -2.6% | -23.3% | +9.2% | +6.3% | +10.6% |
| Depreciation | 0.52 | 0.48 | 0.45 | 0.43 | 0.87 | 0.82 | 0.56 |
| Interest | 0.00 | 0.00 | 0.24 | 0.48 | 0.48 | 1.17 | 0.77 |
| Profit before tax | (3.69) | (6.39) | (1.21) | (4.16) | 12.34 | 2.15 | 1.47 |
| Tax | (0.60) | (1.31) | 0.46 | (1.48) | 0.97 | 0.74 | 0.37 |
| Net profit | (3.09) | 0.26 | (1.51) | 3.77 | 11.37 | 1.41 | 1.10 |
| Net profit margin | -22.0% | +1.2% | -4.2% | +8.3% | +17.4% | +2.5% | +4.6% |
| EPS (₹) | (3.05) | (5.03) | (1.66) | (2.66) | 11.27 | 1.39 | 1.09 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
| Reserves & surplus | 10.57 | 12.76 | 11.76 | 13.11 | 14.07 | 3.59 | 2.46 |
| Shareholders' funds (net worth) | 20.67 | 22.86 | 21.86 | 23.21 | 24.17 | 13.69 | 12.56 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.50 | 0.24 | 0.00 | 0.95 | 10.32 | 16.39 | 11.28 |
| Total debt | 0.50 | 0.24 | 0.00 | 0.95 | 10.32 | 16.39 | 11.28 |
| Total liabilities | 21.17 | 23.10 | 21.86 | 24.16 | 34.49 | 30.08 | 23.84 |
| Assets | |||||||
| Gross block | 2.72 | 2.89 | 3.14 | 3.46 | 2.92 | 4.51 | 4.99 |
| Net block | 2.26 | 2.55 | 2.91 | 3.32 | 2.83 | 4.44 | 4.98 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.26 | 0.26 | 3.39 | 3.76 | 0.26 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.32 |
| Sundry debtors | 2.60 | 4.22 | 7.80 | 9.85 | 12.79 | 11.67 | 14.62 |
| Cash & bank balances | 0.74 | 2.81 | 9.31 | 7.42 | 15.41 | 6.98 | 1.47 |
| Loans & advances | 15.77 | 14.02 | 7.56 | 2.81 | 9.98 | 3.85 | 6.27 |
| Total current assets | 19.11 | 21.05 | 24.67 | 20.08 | 38.22 | 22.54 | 22.68 |
| Total current liabilities | 3.16 | 2.66 | 11.77 | 4.01 | 7.46 | 8.64 | 11.55 |
| Net working capital | 15.95 | 18.39 | 12.90 | 16.07 | 30.76 | 13.90 | 11.13 |
| Total assets | 21.17 | 23.10 | 21.86 | 24.16 | 34.49 | 30.08 | 23.84 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.81 | 9.31 | 7.42 | 15.41 | 6.98 | 1.47 | 0.30 |
| Net cash from operating activities | (2.45) | (9.82) | 4.85 | (1.56) | 8.26 | 1.83 | (15.18) |
| Net cash from investing activities | (0.24) | 3.07 | (1.79) | (4.28) | (1.13) | (0.31) | (0.01) |
| Net cash from financing activities | 0.00 | 0.24 | (1.17) | (2.15) | 1.30 | 3.99 | 16.36 |
| Net change in cash | (2.69) | (6.51) | 1.90 | (7.99) | 8.43 | 5.51 | 1.17 |
| Closing cash | 0.74 | 2.81 | 9.31 | 7.42 | 15.41 | 6.98 | 1.47 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -37.9% | -37.0% | -21.3% | -30.2% | +17.6% | +131.6% | - |
| EBITDA growth | +53.1% | -669.2% | +91.2% | -276.4% | +72.5% | +37.9% | - |
| PBT growth | +42.3% | -428.1% | +70.9% | - | +474.0% | +46.3% | +241.9% |
| Net income growth | -1288.5% | +117.2% | -140.1% | -66.8% | +706.4% | +28.2% | - |
| Revenue CAGR (3Y) | -32.4% | -29.8% | -13.6% | +23.9% | +100.9% | +279.1% | - |
| EBITDA CAGR (3Y) | -31.7% | - | - | - | +139.2% | +252.0% | - |
| Profitability & leverage | |||||||
| Net income margin | -22.0% | -22.5% | -4.7% | -5.9% | +17.4% | +2.5% | +4.6% |
| Return on capital employed | - | -4.7% | -3.1% | +9.5% | +38.0% | +10.8% | +12.3% |
| Return on net worth | - | +1.2% | -6.8% | +15.9% | +55.8% | +8.4% | +8.8% |
| Debt / equity | - | 0.01 | 0.02 | 0.24 | 0.71 | 1.05 | 0.76 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.14 | 0.38 | 0.35 | 0.10 |
| Interest cover | 0.00 | 0.00 | -17.27 | -4.34 | 9.32 | 43.82 | 39.09 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 7.50 | 10.87 | 14.29 | 17.58 | 11.70 | 9.60 |
| Inventory turnover | - | 0.00 | 0.00 | 2,278.50 | 1,633.00 | 308.67 | 74.97 |
| Debtors turnover | - | 3.76 | 4.07 | 4.03 | 5.34 | 4.23 | 2.65 |
| EPS (₹) | (3.05) | (5.03) | (1.66) | (2.66) | 11.27 | 1.39 | 1.09 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 22.63 | 21.64 | 22.98 | 23.93 | 13.55 | 12.44 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.10 | 0.07 | 0.13 | 0.09 | 0.85 | 0.23 | 0.16 | 0.08 |
| Revenue growth (YoY) | -88.2% | -69.6% | -18.8% | +12.5% | +123.7% | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Total expenses | 0.17 | 0.24 | 0.14 | 0.20 | 0.78 | 0.39 | 0.25 | 0.15 |
| EBITDA | (0.07) | (0.17) | (0.01) | (0.11) | 0.07 | (0.16) | (0.09) | (0.07) |
| EBITDA margin | -70.0% | -242.9% | -7.7% | -122.2% | +8.2% | -69.6% | -56.3% | -87.5% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.07) | (0.17) | (0.01) | (0.11) | 0.07 | (0.16) | (0.09) | (0.05) |
| Tax | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.14 | 0.85 | 3.53 | 0.81 | 0.99 | 0.98 | 1.42 |
| Revenue growth | +34.1% | -75.9% | +335.8% | -18.2% | +1.0% | -31.0% | - |
| Other income | 0.00 | 0.02 | 0.02 | 0.03 | 0.05 | 0.14 | 0.01 |
| Total expenses | 1.36 | 1.30 | 3.51 | 3.41 | 0.63 | 0.95 | 1.26 |
| Employee cost | 0.00 | 0.16 | 0.17 | 0.17 | 0.20 | 0.15 | 0.13 |
| EBITDA | (0.22) | (0.45) | 0.02 | (2.60) | 0.36 | 0.03 | 0.16 |
| EBITDA margin | -19.3% | -52.9% | +0.6% | -321.0% | +36.4% | +3.1% | +11.3% |
| Depreciation | 0.02 | 0.02 | 0.01 | 0.06 | 0.05 | 0.04 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Profit before tax | (0.24) | (0.45) | 0.03 | (2.63) | 0.36 | 0.11 | 0.17 |
| Tax | 0.01 | 0.00 | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 |
| Net profit | (0.25) | (0.45) | 0.03 | (0.30) | 0.36 | 0.11 | 0.17 |
| Net profit margin | -21.9% | -52.9% | +0.9% | -37.0% | +36.4% | +11.2% | +12.0% |
| EPS (₹) | (0.24) | (0.44) | 0.02 | (2.59) | 0.36 | 0.10 | 0.17 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
| Reserves & surplus | (1.86) | (1.61) | (1.17) | (1.20) | 1.42 | 1.06 | 0.97 |
| Shareholders' funds (net worth) | 8.24 | 8.49 | 8.93 | 8.90 | 11.52 | 11.16 | 11.07 |
| Secured loans | 0.50 | 0.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 | 0.23 |
| Total debt | 0.50 | 0.24 | 0.00 | 0.00 | 0.00 | 0.14 | 0.23 |
| Total liabilities | 8.74 | 8.73 | 8.93 | 8.90 | 11.52 | 11.30 | 11.30 |
| Assets | |||||||
| Gross block | 0.29 | 0.29 | 0.24 | 0.24 | 0.43 | 0.30 | 0.11 |
| Net block | 0.12 | 0.13 | 0.10 | 0.12 | 0.34 | 0.26 | 0.11 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 8.66 | 8.66 | 8.66 | 8.66 | 8.66 | 8.41 | 8.41 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.32 |
| Sundry debtors | 0.03 | 0.23 | 3.95 | 0.13 | 0.22 | 0.41 | 0.17 |
| Cash & bank balances | 0.03 | 0.05 | 0.03 | 0.06 | 0.05 | 0.02 | 0.03 |
| Loans & advances | 0.10 | 0.04 | 0.00 | 0.00 | 2.29 | 2.25 | 2.60 |
| Total current assets | 0.16 | 0.32 | 3.98 | 0.19 | 2.60 | 2.72 | 3.12 |
| Total current liabilities | 0.25 | 0.45 | 3.83 | 0.09 | 0.08 | 0.10 | 0.35 |
| Net working capital | (0.09) | (0.13) | 0.15 | 0.10 | 2.52 | 2.62 | 2.77 |
| Total assets | 8.74 | 8.73 | 8.93 | 8.90 | 11.52 | 11.30 | 11.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.05 | 0.03 | 0.06 | 0.05 | 0.02 | 0.03 | 0.02 |
| Net cash from operating activities | (0.29) | (0.17) | (0.03) | (0.08) | 0.55 | 0.27 | (0.01) |
| Net cash from investing activities | 0.00 | (0.05) | 0.00 | 0.09 | (0.38) | (0.19) | (0.07) |
| Net cash from financing activities | 0.26 | 0.24 | 0.00 | 0.00 | (0.14) | (0.09) | 0.09 |
| Net change in cash | (0.03) | 0.03 | (0.03) | 0.01 | 0.03 | (0.01) | 0.01 |
| Closing cash | 0.03 | 0.05 | 0.03 | 0.06 | 0.05 | 0.02 | 0.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +34.1% | -75.9% | +335.8% | -18.2% | +1.0% | -31.0% | - |
| EBITDA growth | +51.1% | -2350.0% | +100.8% | -822.2% | +1100.0% | -81.3% | - |
| PBT growth | +46.7% | - | +9998.0% | - | +227.3% | -35.3% | -54.1% |
| Net income growth | +44.4% | -1600.0% | +110.0% | -183.3% | +227.3% | -35.3% | - |
| Revenue CAGR (3Y) | +12.1% | -5.0% | +53.3% | -17.1% | -47.3% | -1.3% | +55.2% |
| EBITDA CAGR (3Y) | -56.1% | - | -12.6% | - | 0.0% | -27.9% | - |
| Profitability & leverage | |||||||
| Net income margin | -21.9% | -52.9% | +0.9% | -322.2% | +36.4% | +11.2% | +12.0% |
| Return on capital employed | - | 0.0% | +0.2% | 0.0% | +2.2% | +0.7% | +1.4% |
| Return on net worth | - | 0.0% | +0.2% | 0.0% | +2.2% | +0.6% | +1.4% |
| Debt / equity | - | 0.01 | 0.00 | 0.00 | 0.01 | 0.02 | 0.03 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -200.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 3.21 | 14.71 | 2.42 | 2.71 | 4.78 | 23.67 |
| Inventory turnover | - | 0.00 | 0.00 | 40.50 | 24.75 | 5.44 | 4.44 |
| Debtors turnover | - | 0.41 | 1.73 | 4.63 | 3.14 | 3.38 | 0.88 |
| EPS (₹) | (0.24) | (0.44) | 0.02 | (2.59) | 0.36 | 0.10 | 0.17 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 8.40 | 8.84 | 8.82 | 11.41 | 11.05 | 10.96 |
To see the full year-wise statements and ratios of Decipher Labs Limited, buy the company report.
Board of directors of Decipher Labs Limited
Decipher Labs has 6 current directors and 14 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Gayathri Raghuram | Director | 04 Sep 2023 | 3 Years 1 Months | Current |
| Sushant Mohan Lal Also directs: Gincom Ventures LLP | Director | 19 May 2006 | 20 Years 5 Months | Current |
| Venkateswara Rao Gudipudi | Director | 13 Aug 2022 | 4 Years 2 Months | Current |
| Lakshmi Vijaya Nimmala | Director | 14 Feb 2023 | 3 Years 8 Months | Current |
| Janaki Ram Ajjarapu Also directs: Icp Solutions Limited | Director | 14 Feb 2023 | 3 Years 8 Months | Current |
| Dalavath Amar Singh | Whole-Time Director | 13 Nov 2025 | 0 Years 11 Months | Current |
Peer comparison
Decipher Labs Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Dagon Pharmaceuticals Private Limited | ₹24.08 Cr (FY 2025) | 3.0% | Vadodara, Gujarat, India | |||
| Lyra Laboratories Private Limited | ₹24.06 Cr (FY 2025) | 1.0% | Buranwala, Himachal Pradesh, India | |||
| Cosmas Pharmacls Limited | ₹23.95 Cr (FY 2025) | 1.0% | Ludhiana, Punjab, India | |||
| Vivek Pharmaceuticals Private Limited | ₹23.84 Cr (FY 2024) | Jaipur, Rajasthan, India | ||||
| Chemgenix Laboratories Private Limited | ₹23.72 Cr (FY 2025) | -1.0% | Hyderabad, Telangana, India | |||
| Decipher Labs Limitedthis company | ₹14.05 Cr (FY 2026) | -₹3.09 Cr | -22% | -37.9% | Hyderabad, Telangana, India |
To see the full peer comparison of Decipher Labs Limited, buy the company report.
Auditor
Decipher Labs Limited is audited by Ramanatham & Rao for the financial year 2022.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Ramanatham & Rao | FY 2022 | S2934 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 16.40%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 83.60%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 16.40% | 16.40% | 16.40% | 16.40% |
| Public | 83.60% | 83.60% | 83.60% | 83.60% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 20 Nov 1996 | 90117170 | The Dhanlakshmi Bank Ltd | ₹40 Lakh | Open | |
| 07 Feb 1989 | 90118244 | Corporation Bank | ₹2.25 Lakh | Open | |
| 16 Jul 1997 | 90118708 | Vijaya Bank | ₹40 Lakh | Satisfied | |
| 21 Nov 1996 | 90117172 | The Dhanlakshmi Bank Ltd | ₹40 Lakh | Satisfied | |
| 07 May 1996 | 90118610 | The Dhanlakshmi Bank Ltd | ₹60 Lakh | Satisfied |
To see the full charge records of Decipher Labs Limited, buy the company report.
Total charge records: 5 View all charges
Deals & funding
Decipher Labs Limited has 38 deals on record (38 market trades); the latest was in June 2024.
Deals on record (5 of 38)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2022 | Market trade | ₹73.8 Lakh | Buyer: Mansi Share and Stock Broking Private Limited Seller: Bhavishya Ecommerce Private Limited , Multiplier Share and Stock Advisors Private Limited , Mansi Share and Stock Broking Private Limited |
| Sep 2022 | Market trade | ₹1.4 Cr | Buyer: Multiplier Share and Stock Advisors Private Limited Seller: Multiplier Share and Stock Advisors Private Limited |
| Sep 2022 | Market trade | ₹12.17 Cr | Buyer: Bhavishya Ecommerce Private Limited , Multiplier Share and Stock Advisors Private Limited , 2 individuals Seller: Bhavishya Ecommerce Private Limited , 3 individuals |
| Sep 2022 | Market trade | ₹11.16 Cr | Buyer: BP Equities Private Limited , Setu Securities Private Limited , 2 individuals Seller: BP Equities Private Limited , 3 individuals |
| Sep 2022 | Market trade | ₹6.29 Cr | Buyer: BP Equities Private Limited , Multiplier Share and Stock Advisors Private Limited , an individual Seller: BP Equities Private Limited , Multiplier Share and Stock Advisors Private Limited , 2 individuals |
To see the full deal history of Decipher Labs Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Decipher Labs Limited has 13 court cases on record: 5 filed by Decipher Labs, 8 filed against it. 3 cases are pending and 10 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 8 | 6 | 3 |
| High courts | 5 | 2 | 0 |
Cases on record (5 of 13)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, TELANGANA | Court case (CRLRC) | Filed by the company against Andhra Pradesh Industrial Development Corporation Ltd. | Disposed |
| District court, Mumbai City Civil Court, Maharashtra | Civil suit | Filed against the company by Bajaj Pharmaceuticals Bombay Ltd | Disposed |
| District court, Hyderabad Central, Telangana | Petition | Filed against the company by individuals | Pending |
| District court, East Godavari, Andhra Pradesh | Appeal | Filed against the company by individuals | Pending |
| District court, Hyderabad Central, Telangana | Court case (CC - NI) | Filed by the company against M/S Spire (India) Remedies Rep by K.A. Jagtap and 1 other | Pending |
To see the full case history of Decipher Labs Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Decipher Labs Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Decipher Labs has 1 subsidiary company. This group structure data is as of FY 2021. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Icp Solutions Private Limited | U72500TG2018PTC124743 |
To see the full group structure of Decipher Labs Limited, buy the company report.
GST
No GST registration is on our record for Decipher Labs Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Decipher Labs Limited has 18 board changes on record since 2006: 6 appointments and 12 cessations. The latest: Dalavath Amar Singh was appointed as Whole-Time Director on 13 Nov 2025.
19 earlier events are in the company report.
Frequently asked questions
Decipher Labs is an active public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 17 September 1986 (40+ years old) and is registered under CIN L24230TG1986PLC006781. Listed on BSE: 524752.
Decipher Labs reported revenue of ₹14.05 Cr for FY 2025-26 (down 37.9% YoY) based on consolidated financials.
Decipher Labs has 6 current directors:
- Dalavath Amar Singh - Whole-Time Director
- Gayathri Raghuram - Director
- Sushant Mohan Lal - Director
- Venkateswara Rao Gudipudi - Director
- Lakshmi Vijaya Nimmala - Director
- Janaki Ram Ajjarapu - Director
The latest financial statements of Decipher Labs on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Decipher Labs is L24230TG1986PLC006781. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Decipher Labs is a listed company as per MCA records. Its shares are listed on BSE (code: 524752).
Decipher Labs has 13 court cases on record: 5 filed by the company and 8 filed against it. 3 are pending. Most are in the district courts.
Decipher Labs was incorporated on 17 September 1986, making it 40+ years old. It is registered with the Registrar of Companies, Hyderabad.
Decipher Labs has 38 deals on record (38 market trades); the latest was in June 2024.
The peers of Decipher Labs by revenue are Dagon Pharmaceuticals Private Limited, Lyra Laboratories Private Limited, Cosmas Pharmacls Limited, Vivek Pharmaceuticals Private Limited, Chemgenix Laboratories Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Dalavath Amar Singh was appointed as Whole-Time Director on 13 Nov 2025. Ankita Mathur ceased to be Additional Director on 14 Aug 2025. Gayathri Raghuram was appointed as Director on 04 Sep 2023. Decipher Labs has 18 board changes on record in total.